Posted by Maria3667 on February 3, 2009, at 8:50:40
In reply to flibanserin pimavanserin eplivanserin volinanserin, posted by iforgotmypassword on February 3, 2009, at 7:31:57
Hi Iforgot,
Well I really only know about Flibanserin as it is dubbed as the first female aphrodisiac and I've been following it for a while now. I know the company is conducting third fase tests around the world, involving thousands of subjects. To the best of my knowledge, it won't go to the FDA or EMEA (Europe) until 2010 (optimistic guess).
The other meds you mention, I've never even heard off...
> which has the best chance of being released? which may be the soonest? any sort of time-frames indicated lately? does anyone know where this drugs are in terms of approval in the united states and/or canada, or anywhere?
>
> flibanserin seems very interesting as it doesn't seem to be an SRI (unlike the other 5-HT2a antagonist nefazodone), and could in an important way be opposite in effect as a 5-HT1a (partial?) agonist. i am concerned with alieviating extrapyramidal symptoms, increasingly unreliable mobility, and broad mental deadening (apathy, avolition, amotivation, loss of creativity, loss of real appreciation of anything artistically, loss of meaningful spontaneous fluency) that may be a consequence of excessive serotonergic input that didn't remedy after taking SSRIs.
>
> pimavanserin may also be very interesting, especially while also being an M1 agonist in addition to it's 5-HT2/D2,3 effects, but they will have to elaborate on how it operates as a D2,3 partial agonist, if it stays on the agonist side of things under all situations particularly in the striatum. (a problem with aripiprazole) pimavanserin to my knowledge has no 5-HT1a affinity, but i may be wrong, it would be very interesting if it is also a meaningful 5-HT1A agonist/partial-agonist.
poster:Maria3667
thread:877770
URL: http://www.dr-bob.org/babble/20090203/msgs/877781.html